Patrizia Giannatempo

List of Publications by Year
in descending order

96 papers	3,086 citations	236912 25 h-index	175241 52 g-index
97 all docs	97 docs citations	97 times ranked	3476 citing authors

#	Article	IF	Citations
1	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology, 2018, 36, 3353-3360.	1.6	474
2	ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, 1658-1686.	1.2	228
3	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. European Urology, 2020, 77, 439-446.	1.9	228
4	Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncology, The, 2012, 13, 810-816.	10.7	130
5	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 701-710.	1.9	128
6	Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Annals of Oncology, 2016, 27, 49-61.	1.2	108
7	The Relationship between Characteristics of Inguinal Lymph Nodes and Pelvic Lymph Node Involvement in Penile Squamous Cell Carcinoma: A Single Institution Experience. Journal of Urology, 2014, 191, 977-982.	0.4	75
8	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. European Urology, 2020, 77, 636-643.	1.9	75
9	Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Annals of Oncology, 2015, 26, 657-668.	1.2	71
10	Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. Journal of Urology, 2016, 196, 95-100.	0.4	70
11	Firstâ€line therapy with dacomitinib, an orally available panâ€HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an openâ€label, singleâ€arm, singleâ€centre, phase 2 study. BJU International, 2018, 121, 348-356.	2.5	70
12	Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Optionsâ€”An Analysis From the Global Germ Cell Cancer Group. Journal of Clinical Oncology, 2016, 34, 345-351.	1.6	69
13	A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings. Clinical Genitourinary Cancer, 2016, 14, 323-330.	1.9	59
14	Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma. Journal of Clinical Oncology, 2010, 28, 1322-1328.	1.6	58
15	An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis. European Urology, 2019, 75, 201-203.	1.9	54
16	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor Î² (TGFÎ²) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. Investigational New Drugs, 2014, 32, 555-560.	2.6	50
17	Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Clinical Genitourinary Cancer, 2017, 15, 23-30.e2.	1.9	50
18	Clinical Outcome in Testicular Sex Cord Stromal Tumors: Testis Sparing vs Radical Orchiectomy and Management of Advanced Disease. Urology, 2015, 85, 402-406.	1.0	47

#	Article	IF	Citations
19	Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. Clinical Genitourinary Cancer, 2016, 14, 231-236.	1.9	38
20	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. Clinical Genitourinary Cancer, 2017, 15, 548-555.e3.	1.9	37
21	Patients Selection for Immunotherapy in Solid Tumors: Overcome the NaÃ¯ve Vision of a Single Biomarker. BioMed Research International, 2019, 2019, 1-15.	1.9	37
22	Persistent CD30 Expression by Embryonal Carcinoma in the Treatment Time Course: Prognostic Significance of a Worthwhile Target for Personalized Treatment. Journal of Urology, 2013, 190, 1919-1924.	0.4	36
23	Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. Annals of Oncology, 2017, 28, 1346-1351.	1.2	34
24	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. Journal of the National Cancer Institute, 2021, 113, 48-53.	6.3	30
25	Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma After Regional Lymphadenectomy. Clinical Genitourinary Cancer, 2016, 14, 518-523.	1.9	28
26	Combination of Paclitaxel, Cisplatin, and Gemcitabine (TPG) for Multiple Relapses or Platinum-Resistant Germ Cell Tumors: Long-Term Outcomes. Clinical Genitourinary Cancer, 2014, 12, 63-69.e1.	1.9	27
27	Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. Therapeutic Advances in Urology, 2015, 7, 152-161.	2.0	27
28	A Prognostic Model Including Pre- and Postsurgical Variables to Enhance Risk Stratification of Primary Mediastinal Nonseminomatous Germ Cell Tumors: The 27-Year Experience of a Referral Center. Clinical Genitourinary Cancer, 2015, 13, 87-93.e1.	1.9	27
29	Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies. Clinical Genitourinary Cancer, 2017, 15, 213-220.e5.	1.9	27
30	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. Journal of Urology, 2018, 200, 1207-1214.	0.4	26
31	The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. European Urology, 2016, 69, 624-633.	1.9	25
32	A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors. Clinical Genitourinary Cancer, 2017, 15, 306-312.e3.	1.9	25
33	Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Therapeutic Response to Chemotherapy for Metastatic Transitional Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 433-439.	1.9	24
34	Relationship between lymph node ratio and cancer-specific survival in a contemporary series of patients with penile cancer and lymph node metastases. BJU International, 2015, 116, 727-733.	2.5	23
35	Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. European Urology Oncology, 2021, 4, 1001-1005.	5.4	23
36	Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure. Clinical Genitourinary Cancer, 2016, 14, 261-264.e4.	1.9	22

#	Article	IF	Citations
37	Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. European Urology Oncology, 2021, 4, 802-810.	5.4	22
38	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. Investigational New Drugs, 2016, 34, 236-242.	2.6	21
39	Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. Journal of Urology, 2018, 199, 741-747.	0.4	21
40	Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients. Journal of Endourology, 2016, 30, 1112-1119.	2.1	20
41	The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. European Urology Oncology, 2021, 4, 829-833.	5.4	20
42	Palliative treatment of germ cell cancer. Cancer Treatment Reviews, 2018, 71, 102-107.	7.7	19
43	Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets. European Urology Focus, 2018, 4, 733-736.	3.1	18
44	Postchemotherapy Lymphadenectomy in Patients With Metastatic Urothelial Carcinoma: Long-Term Efficacy and Implications for Trial Design. Clinical Genitourinary Cancer, 2015, 13, 80-86.e1.	1.9	17
45	High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. Annals of Oncology, 2015, 26, 167-172.	1.2	17
46	Erdafitinib for the treatment of urothelial cancer. Expert Review of Anticancer Therapy, 2019, 19, 835-846.	2.4	17
47	Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. British Journal of Cancer, 2014, 110, 26-33.	6.4	16
48	Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 159, 103241.	4.4	16
49	Long-Term Efficacy and Safety Outcomes of Modified (Simplified) MVAC (Methotrexate/Vinblastine/Doxorubicin/Cisplatin) as Frontline Therapy for Unresectable or Metastatic Urothelial Cancer. Clinical Genitourinary Cancer, 2014, 12, 203-209.e1.	1.9	15
50	Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy. Clinical Genitourinary Cancer, 2015, 13, 178-184.	1.9	15
51	Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes. Annals of Oncology, 2013, 24, 2887-2892.	1.2	14
52	Clinical Significance of Early Changes inÂCirculating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma1. Bladder Cancer, 2016, 2, 395-403.	0.4	13
53	Epidemiology and unmet needs of bladder cancer in Italy: a critical review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 1-12.	3.9	13
54	Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 332.e19-332.e24.	1.6	12

#	Article	IF	Citations
55	Interim 18F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions. Clinical Genitourinary Cancer, 2016, 14, 249-254.	1.9	12
56	Cisplatin- Versus Nonâ€“Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. Clinical Genitourinary Cancer, 2016, 14, 331-340.	1.9	12
57	Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research. Clinical Genitourinary Cancer, 2018, 16, e403-e410.	1.9	11
58	Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?. European Urology Oncology, 2021, 4, 1006-1010.	5.4	11
59	An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01).. Journal of Clinical Oncology, 2016, 34, 480-480.	1.6	11
60	[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e15-235.e21.	1.6	10
61	Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy. Clinical Genitourinary Cancer, 2015, 13, 171-177.e1.	1.9	9
62	Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib. Investigational New Drugs, 2017, 35, 524-528.	2.6	9
63	Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure. European Journal of Cancer, 2018, 96, 128-130.	2.8	9
64	Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 8.e1-8.e8.	1.6	8
65	Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort. European Urology Focus, 2019, 5, 853-856.	3.1	8
66	Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. Bone Marrow Transplantation, 2016, 51, 384-390.	2.4	7
67	Treatment of Carcinoma In Situ of the Glans Penis With Topical Imiquimod Followed by Carbon Dioxide Laser Excision. Clinical Genitourinary Cancer, 2017, 15, e483-e487.	1.9	7
68	Quality of Life and Pain Control following Laparoscopic Retroperitoneal Lymph Node Dissection in Early-stage Nonseminoma. Tumori, 2015, 101, 650-656.	1.1	6
69	The Changing Landscape of Intermediate- and Poor-Risk Germ Cell Tumors: Do We Need to Reclassify Patients With Metastatic Germ Cell Tumors?. Clinical Genitourinary Cancer, 2016, 14, 1-4.	1.9	6
70	Immunotherapy for metastatic urothelial carcinoma. Current Opinion in Urology, 2018, 28, 1-7.	1.8	6
71	Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage.. Journal of Clinical Oncology, 2018, 36, 4547-4547.	1.6	6
72	Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2018, 53, 722-728.	2.4	5

#	Article	IF	Citations
73	Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica. Critical Reviews in Oncology/Hematology, 2019, 137, 154-164.	4.4	5
74	Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment. Clinical Genitourinary Cancer, 2021, 19, 237-245.e2.	1.9	5
75	Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial.. Journal of Clinical Oncology, 2014, 32, 376-376.	1.6	5
76	Nausea and Vomiting during the First 3 Intercycle Periods in Chemo-naive Cancer Patients Receiving Moderately/Highly Emetogenic Therapy. Tumori, 2015, 101, 692-696.	1.1	4
77	Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center. Clinical Genitourinary Cancer, 2015, 13, 385-391.e1.	1.9	4
78	Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, e81-e90.	1.9	4
79	Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 60-65.	1.3	4
80	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. European Urology Focus, 2021, 7, 1092-1099.	3.1	4
81	Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database. Bone Marrow Transplantation, 2017, 52, 1218-1220.	2.4	4
82	Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). Immunotherapy, 2022, 14, 107-114.	2.0	4
83	Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain FGFR genetic alterations. Future Oncology, 2022, 18, 2455-2464.	2.4	4
84	Predictors of CD34+ Cell Mobilization and Collection in Adult Men With Germ Cell Tumors: Implications for the Salvage Treatment Strategy. Clinical Genitourinary Cancer, 2014, 12, 196-202.e1.	1.9	3
85	Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012. Clinical Genitourinary Cancer, 2017, 15, 163-167.	1.9	3
86	An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas. Expert Opinion on Pharmacotherapy, 2020, 21, 2199-2204.	1.8	3
87	Etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine (EMA/CO) for males with HCG-expressing, chemorefractory germ cell tumors (GCT): Long-term efficacy and safety outcomes.. Journal of Clinical Oncology, 2014, 32, 4561-4561.	1.6	2
88	Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers. Biologics: Targets and Therapy, 2021, Volume 15, 441-450.	3.2	2
89	Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 494-498.	1.9	1
90	From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. Clinical Genitourinary Cancer, 2017, 15, 509-512.e9.	1.9	1

#	Article	IF	Citations
91	Nivolumab and its use in the second-line treatment of metastatic urothelial cancer. Future Oncology, 2018, 14, 2683-2690.	2.4	1
92	Comparison of Fibroblast Growth-factor Receptor Gene Alterations at the DNA versus Messenger RNA Level in Advanced Urothelial Cancer: Insights for Clinical Research. European Urology Focus, 2019, 5, 689-692.	3.1	1
93	Prostatic metastases from testicular nonseminomatous germ cell cancer: two case reports and a review of the literature. Tumori, 2013, 99, e203-7.	1.1	1
94	New Directions for Biologic Targets in Urothelial Carcinoma â€“ Letter. Molecular Cancer Therapeutics, 2012, 11, 2306-2306.	4.1	0
95	Role of Neoadjuvant and Adjuvant Chemotherapy in Penile Cancer. , 2018, , 1-6.		0
96	Role of Neoadjuvant and Adjuvant Chemotherapy in Penile Cancer. , 2019, , 845-850.		0